Europe follows, driven by guideline-directed medical therapy adoption
But the CagriSema data is important because it proves a principle Ive been applying for decades: MULTI-PATHWAY interventions tend to outperform single-pathway approaches
Les tudes cliniques sur le glutathion oral ont utilis des doses allant de 250 1 000 mg par jour, sur des dures de un six mois
Eva Kamensk
Should retatrutide receive future regulatory approval, any UK prescribing would be subject to MHRA marketing authorisation, and access would likely be governed through the standard NICE technology appraisal process as is the case for existing obesity pharmacotherapies
Last reviewed: July 2, 2026 Last updated: July 2, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations